Literature DB >> 26883716

MiR-204 inhibits the proliferation and invasion of renal cell carcinoma by inhibiting RAB22A expression.

Feng Xiong1, Keyun Liu1, Fumei Zhang1, Kaihui Sha1, Xinyuan Wang1, Xiaojuan Guo1, Ning Huang1.   

Abstract

While miR-204 expression may be linked to renal cell carcinoma (RCC) progression, the detailed mechanisms remain unclear. In the present study, we demonstrated that miR-204 was differentially expressed in RCC tissues when compared with surrounding normal kidney tissues. Ectopic overexpression of miR-204 in human RCC cells suppressed cell proliferation and invasion in vitro and in vivo. Mechanism dissection revealed that miR-204 may function through RAB22A signals to inhibit RCC proliferation and invasion. Overexpression of RAB22A by oe-RAB22A was able to partially reverse the miR-204-mediated suppression of RCC tumor progression. Together, these results revealed that miR-204 suppressed RCC proliferation and invasion by directly targeting the RAB22A gene. Targeting newly identified RAB22A with miR-204 may aid in the suppression of RCC proliferation and invasion.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26883716     DOI: 10.3892/or.2016.4624

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  20 in total

1.  MicroRNA-204 attenuates oxidative stress damage of renal tubular epithelial cells in calcium oxalate kidney-stone formation via MUC4-mediated ERK signaling pathway.

Authors:  Zhijuan Xie; Jianying Chen; Zhong Chen
Journal:  Urolithiasis       Date:  2021-11-16       Impact factor: 3.436

2.  Rab22a Promotes Epithelial-Mesenchymal Transition in Papillary Thyroid Carcinoma by Activating PI3K/AKT/mTOR Signaling Pathway.

Authors:  Xue Luo; Jinping Wang; Jinxi Lu; Xi Wang; Yuan Miao; Qingchang Li; Xiaoman Li; Liang Wang
Journal:  Biomed Res Int       Date:  2022-06-15       Impact factor: 3.246

3.  miR-486-3p, miR-139-5p, and miR-21 as Biomarkers for the Detection of Oral Tongue Squamous Cell Carcinoma.

Authors:  Zujian Chen; Tianwei Yu; Robert J Cabay; Yi Jin; Ishrat Mahjabeen; Xianghong Luan; Lei Huang; Yang Dai; Xiaofeng Zhou
Journal:  Biomark Cancer       Date:  2017-01-09

4.  MicroRNA-154 as a prognostic factor in bladder cancer inhibits cellular malignancy by targeting RSF1 and RUNX2.

Authors:  Xin Zhao; Zhigang Ji; Yi Xie; Guanghua Liu; Hanzhong Li
Journal:  Oncol Rep       Date:  2017-09-25       Impact factor: 3.906

5.  The protective value of miR-204-5p for prognosis and its potential gene network in various malignancies: a comprehensive exploration based on RNA-seq high-throughput data and bioinformatics.

Authors:  Zhi-Hua Ye; Dong-Yue Wen; Xiao-Yong Cai; Liang Liang; Pei-Rong Wu; Hui Qin; Hong Yang; Yun He; Gang Chen
Journal:  Oncotarget       Date:  2017-10-23

6.  Role of miR-520b in non-small cell lung cancer.

Authors:  Linlin Zhang; Shuangquan Yu
Journal:  Exp Ther Med       Date:  2018-09-12       Impact factor: 2.447

7.  Integrative Analyses of Transcriptome Sequencing Identify Functional miRNAs in the Chicken Embryo Fibroblasts Cells Infected With Reticuloendotheliosis Virus.

Authors:  Jie Zhai; Chang Gao; Lisheng Fu; Long Jing; Shengyuan Dang; Shimin Zheng
Journal:  Front Genet       Date:  2018-08-29       Impact factor: 4.599

8.  RAB22A overexpression promotes the tumor growth of melanoma.

Authors:  Feng Su; Yifei Chen; Shilin Zhu; Fangfang Li; Shuang Zhao; Lisa Wu; Xiang Chen; Juan Su
Journal:  Oncotarget       Date:  2016-11-01

9.  Identification of eight key miRNAs associated with renal cell carcinoma: A meta-analysis.

Authors:  Guanghui Ying; Ruilan Wu; Min Xia; Xiapei Fei; Qi En He; Chenqin Zha; Fuquan Wu
Journal:  Oncol Lett       Date:  2018-09-03       Impact factor: 2.967

10.  Weighted Gene Coexpression Network Analysis to Construct Competitive Endogenous RNA Network in Chromogenic Renal Cell Carcinoma.

Authors:  Yong-Bo Chen; Liang Gao; Jin-Dong Zhang; Jiang Guo; Ping-Hong You; Liang-You Tang; Ying-Wen Liu
Journal:  Biomed Res Int       Date:  2021-06-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.